Current position of viral load versus hepatitis C core antigen testing

被引:0
作者
Aguilera, Antonio [1 ,2 ]
Carlos Alados, Juan [3 ]
Alonso, Roberto [4 ]
Maria Eiros, Jose [5 ]
Garcia, Federico [6 ,7 ]
机构
[1] Univ Santiago de Compostela, Complejo Hosp Univ Santiago de Compostela, Serv Microbiol, La Coruna, Spain
[2] Univ Santiago de Compostela, Dept Microbiol, La Coruna, Spain
[3] Hosp Univ Jerez, Serv Microbiol, Cadiz, Spain
[4] Hosp Univ Gregorio Maranon, Serv Microbiol, Madrid, Spain
[5] Hosp Univ Rio Hortega, Serv Microbiol, Valladolid, Spain
[6] Hosp Univ San Cecilio, Serv Microbiol, Granada, Spain
[7] Inst Invest Biosanitaria IbsGranada, Granada, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2020年 / 38卷
关键词
Hepatitis C; Diagnosis; Treatment; Core antigen; Viral load; APASL CONSENSUS STATEMENTS; HCV RNA; ENZYME-IMMUNOASSAY; MANAGEMENT; INFECTION; DIAGNOSIS; ASSAY; ERA; RECOMMENDATIONS; SAMPLES;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Quantification of hepatitis C virus (HCV) RNA (viral load) is the most widely used marker to diagnose and confirm active HCV infection. The HCV core antigen forms part of the internal structure of the virus and, like HCV RNA, its detection also indicates viral replication and presents certain advantages over viral load testing such as its lower cost, the greater stability of the target, the possibility of working with the same primary tube as that used for HCV serology, and the rapidity of obtaining results, since there is no need to work in batches, unlike the situation with most viral load platforms. Although the core antigen has lower analytical sensitivity than HCV RNA for the detection of low viremia levels, several studies and guidelines have already shown their utility in the identification of patients with active HCV infection. This article summarises current platforms for viral load determination, including point-of-care systems, and also reviews the indica-tions attributed to this marker by the main HCV treatment guidelines. The article also reviews the characteristics of HCV core antigen, the available platforms for its determination, its correlation with viral load determination, and the indications for this marker in the distinct guidelines. (C) 2020 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 56 条
  • [11] A pilot study on the implementation of reflex testing for the diagnosis of active hepatitis C virus infection at two healthcare centres
    Casas, Paz
    Navarro, Daniel
    Aguilera, Antonio
    Garcia, Federico
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2019, 37 (05): : 348 - 349
  • [12] Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen
    Chevaliez, Stephane
    Feld, Jordan
    Cheng, Kevin
    Wedemeyer, Heiner
    Sarrazin, Christoph
    Maasoumy, Benjamin
    Herman, Christine
    Hackett, John
    Cohen, Daniel
    Dawson, George
    Pawlotsky, Jean-Michel
    Cloherty, Gavin
    [J]. ANTIVIRAL THERAPY, 2018, 23 (03) : 211 - 217
  • [13] Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
    Chung, Raymond T.
    Ghany, Marc G.
    Kim, Arthur Y.
    Marks, Kristen M.
    Naggie, Susanna
    Vargas, Hugo E.
    Aronsohn, Andrew I.
    Bhattacharya, Debika
    Broder, Tina
    Falade-Nwulia, O.
    Fontana, Robert J.
    Gordon, Stuart C.
    Heller, Theo
    Holmberg, Scott D.
    Jhaveri, Ravi
    Jonas, Maureen M.
    Kiser, Jennifer J.
    Linas, Benjamin P.
    Lo Re, Vincent, III
    Morgan, Timothy R.
    Nahass, Ronald G.
    Peters, Marion G.
    Reddy, K. Rajender
    Reynolds, Andrew
    Scott, John D.
    Searson, Gloria
    Swan, Tracy
    Terrault, Norah A.
    Trooskin, Stacey B.
    Wong, John B.
    Workowski, Kimberly A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 67 (10) : 1477 - 1492
  • [14] Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection
    Cloherty, Gavin
    Talal, Andrew
    Coller, Kelly
    Steinhart, Corklin
    Hackett, John, Jr.
    Dawson, George
    Rockstroh, Juergen
    Feld, Jordan
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2016, 54 (02) : 265 - 273
  • [15] Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
    Cobb, Bryan
    Heilek, Gabrielle
    Vilchez, Regis A.
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [16] HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals
    Cobb, Bryan
    Pockros, Paul J.
    Vilchez, Regis A.
    Vierling, John M.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (04) : 471 - 475
  • [17] The efficiency of several one-step testing strategies for the diagnosis of hepatitis C
    Crespo, Javier
    Maria Eiros-Bouza, Jose
    Javier Blasco-Bravo, Antonio
    Lazaro-de-Mercado, Pablo
    Aguilera-Guirao, Antonio
    Garcia, Federico
    Garcia-Samaniego-Rey, Javier
    Luis Calleja-Panero, Jose
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (01) : 10 - 16
  • [18] Evaluation of dried blood spot samples for hepatitis C virus detection and quantification
    Crespo Marques, Brunna Lemos
    do Espirito-Santo, Marcia Paschoal
    Marques, Vanessa Alves
    Miguel, Juliana Custodio
    da Silva, Elisangela Ferreira
    Villela-Nogueira, Cristiane Alves
    Lewis-Ximenez, Lia Laura
    Lampe, Elisabeth
    Villar, Livia Melo
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2016, 82 : 139 - 144
  • [19] EASL Recommendations on Treatment of Hepatitis C 2018
    Pawlotsky J.-M.
    Negro F.
    Aghemo A.
    Berenguer M.
    Dalgard O.
    Dusheiko G.
    Marra F.
    Puoti M.
    Wedemeyer H.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (02) : 461 - 511
  • [20] Forum for Collaborative HIV Research Foundation for Innovative New Diagnostics, 2015, HIGH PRIOR TARG PROD